Inhibikase Therapeutics, Inc. (IKT): director Dennis Berman resigned

Events in this filing

Item 5.02 as filed

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Dennis Berman
On October 19, 2026, Dennis Berman resigned from the board of directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) and his position as Chair of the Compensation Committee of the Board (the “Compensation Committee”) and a member of the Audit Committee of the Board (the “Audit Committee”), effective as of October 19, 2026. Mr. Berman advised the Company that his decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices.
Appointment of Scott Wasserman
On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”). In addition, Dr. Wasserman will serve as a member of the Compensation Committee. The Board has determined that Dr. Wasserman is independent under the applicable listing standards of The Nasdaq Stock Market LLC and the rules and regulations of the Securities and Exchange Commission.
In connection with his appointment to the Board, Dr. Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of the Company’s common stock, and cash compensation for his Board and committee service, in accordance with the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time.
There are no arrangements or understandings between Dr. Wasserman and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Dr. Wasserman has a material interest subject to disclosure under Item 404(a) of Regulation S-K. In addition, Dr. Wasserman entered into an indemnification agreement with the Company consistent with the form of indemnification agreement, a copy of which has been previously filed with the Company’s most recent Annual Report on Form 10-K.